Al Hammadi Company for Development and Investment reported a net profit of SAR 107.96 million for fiscal year 2017, a 47.97 percent year-on-year (YoY) increase.
The company said the increase in net profit is attributable to a 17 percent rise in revenue due to higher numbers of patients and optimized contractual terms with customers.
Item | 2016 | 2017 | Change |
---|---|---|---|
Revenues | 606.24 | 708.62 | 16.9 % |
Gross Income | 242.13 | 239.16 | (1.2 %) |
Operating Income | 98.81 | 126.88 | 28.4 % |
Net Income | 72.96 | 107.97 | 48.0 % |
Average Shares | 160.00 | 160.00 | - |
Earnings Per Share before unusual items (Riyals) | 0.46 | 0.67 | 48.0 % |
EPS (Riyal) | 0.46 | 0.67 | 48.0 % |
The company posted a net profit of SAR 30.76 million in the fourth quarter of 2017.
Item | Q4 2016 | Q4 2017 | Change |
---|---|---|---|
Revenues | 182.65 | 188.69 | 3.3 % |
Gross Income | 73.35 | 65.08 | (11.3 %) |
Operating Income | 18.58 | 33.93 | 82.6 % |
Net Income | 10.48 | 30.76 | 193.4 % |
Average Shares | 160.00 | 160.00 | - |
Earnings Per Share before unusual items (Riyal) | 0.07 | 0.19 | 193.4 % |
EPS (Riyal) | 0.07 | 0.19 | 193.4 % |
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
Q1 2017 | 180.23 | 25.0 % | 62.02 | 13.3 % | 33.61 | 26.0 % |
Q2 2017 | 176.71 | 28.0 % | 58.16 | 1.0 % | 32.88 | 19.0 % |
Q3 2017 | 163.01 | 15.3 % | 53.91 | (4.5 %) | 26.46 | 1.9 % |
Q4 2017 | 188.69 | 3.3 % | 65.08 | (11.3 %) | 33.93 | 82.6 % |
2017 | 708.62 | 16.9 % | 239.16 | (1.2 %) | 126.88 | 28.4 % |
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS(Riyal) |
---|---|---|---|---|---|---|
Q1 2017 | 27.97 | 32.3 % | 0.17 | - | 27.97 | 0.17 |
Q2 2017 | 25.66 | 24.4 % | 0.16 | - | 25.66 | 0.16 |
Q3 2017 | 23.59 | 13.8 % | 0.15 | - | 23.59 | 0.15 |
Q4 2017 | 30.76 | 193.4 % | 0.19 | - | 30.76 | 0.19 |
2017 | 107.97 | 48.0 % | 0.67 | - | 107.97 | 0.67 |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
Q1 2016 | 42.42 % | 30.79 % | 21.09 % |
Q2 2016 | 41.32 % | 30.64 % | 18.24 % |
Q3 2016 | 40.74 % | 29.96 % | 16.90 % |
Q4 2016 | 39.94 % | 25.11 % | 12.04 % |
2016 | 39.94 % | 25.10 % | 12.03 % |
Q1 2017 | 38.83 % | 24.74 % | 12.43 % |
Q2 2017 | 36.71 % | 24.09 % | 12.46 % |
Q3 2017 | 35.22 % | 23.41 % | 12.48 % |
Q4 2017 | 33.75 % | 25.39 % | 15.24 % |
2017 | 33.75 % | 25.39 % | 15.24 % |
Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
---|---|---|---|---|
Q1 2017 | 160.00 | 0.50 | 0.50 | 8.75 |
Q2 2017 | 160.00 | 0.53 | 0.53 | 8.89 |
Q3 2017 | 160.00 | 0.55 | 0.55 | 9.04 |
Q4 2017 | 160.00 | 0.67 | 0.67 | 8.67 |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
Q1 2017 | 61.37 | 61.37 | 3.50 |
Q2 2017 | 58.51 | 58.51 | 3.49 |
Q3 2017 | 47.94 | 47.94 | 2.91 |
Q4 2017 | 41.25 | 41.25 | 3.21 |
Q4 2017
Period | Healthcare services | Pharmaceutical sales revenue - Pharmacies |
---|---|---|
Q1 2017 | 150.74 | 29.49 |
Q2 2017 | 147.45 | 29.26 |
Q3 2017 | 136.70 | 26.31 |
Q4 2017 | 155.95 | 32.73 |
Item | Profit (Expected) | Profit (Actual) | Change |
---|---|---|---|
Average | 27.89 | 30.76 | 10.29 % |
Item | Profit (Expected) | Profit (Actual) | Change |
---|---|---|---|
Sico | 30.00 | 30.76 | 2.5 % |
AlJazira Capital | 29.20 | 30.76 | 5.1 % |
Alistithmar Capital | 29.20 | 30.76 | 5.1 % |
Al Rajhi Capital | 28.00 | 30.76 | 9.0 % |
OSOOL AND BAKHEET | 27.50 | 30.76 | 10.6 % |
SNB Capital | 27.00 | 30.76 | 12.2 % |
Arbah Capital | 26.20 | 30.76 | 14.8 % |
Albilad Capital | 26.00 | 30.76 | 15.5 % |
Current | |
Market Cap (M Riyal) | 6,028.81 |
Enterprise Value (EV) (M) | 6,027.65 |
Shares Outstanding ((M)) | 160.00 |
EPS ( Riyal) (TTM) | 2.18 |
Book Value (BV) ( Riyal) | 12.38 |
Par Value ( Riyal) | 10.00 |
Recurring P/E | 20.55 |
P/E (TTM) | 17.29 |
Price/book | 3.04 |
Return on Average Assets (%) (TTM) | 13.2 |
Return on Average Equity (%) (TTM) | 18.2 |
EV/adj EBITDA | 16.30 |
EV/Revenues | 5.23 |
Be the first to comment
Comments Analysis: